Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Biopharma Segment by Year
Biopharma Segment — Acquired in-process R&D (IPR&D) ($M) ($M)
Pfizer Biopharma Segment: $113M in FY2025, up 4.6% from a year earlier.
Latest, FY2025
113
Period ended Dec 31, 2025
Change on a year earlier
+4.6%
108 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K Note 17 — Segment Reporting (ASU 2023-07 Significant Segment Expenses).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biopharma Segment — Acquired in-process R&D (IPR&D) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 113 | +4.6% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 108 | -44.3% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 194 | +7.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 181 | – | Form 10-K (filed 2025-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer Biopharma Segment ($M), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/seg-iprd-bio
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.